we reach people

The most advanced drugs are of no use if patients don’t
have access to them. Biologics are a case in point.

no matter where

There is an urgent need for increased access to
biologics in many underserved regions, countries and
emerging markets around the world.

Viatris has successfully introduced
biosimilars in 76 countries with the first
one approved in the US in 2018. What
others hope to do in the future, Viatris is
delivering today.

it’s what we do

Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind GLOBAL HEALTHCARE GATEWAY®.

Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a growing portfolio of biosimilars.